A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML) - N/A

ovartis Pharma Services AG0 个研究点目标入组 0 人开始时间: 2009年7月6日最近更新: 2020年7月27日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: ovartis Pharma Services AG

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•5.1.1 Stratum A Specific Inclusion Criterion
•1. Refractory AML with confirmed initial diagnosis of de novo AML (excluding APL)
•5.1.2 Stratum B Specific Inclusion Criterion
•Refractory AML with confirmed initial diagnosis of AML (excluding APL) secondary to precedent AHD or MDS with either condition being diagnosed at least three months before confirmed diagnosis of AML. [Patients may have received no prior treatment or treatment with conventional care regimens, including best supportive care, low dose cytarabine, intensive chemotherapy, hypomethylating agents (azacitidine, decitabine), or other therapies (e.g. lenalidomide)] for precedent MDS.
•5.1.3 Stratum A or B General Inclusion Criteria
•1. Written informed consent prior to study-specific screening procedures
•2. Age = 18 years old
•3. Patients with refractory AML (according to Estey 1996b) whose disease:
•is primary refractory (= no complete remission following initial induction therapy) or
•has relapsed within 12 months after CR1 and for whom salvage (re-induction) chemotherapy is not indicated for documented clinical reasons or documented patient refusal or
•has relapsed within 12 months after CR1 and patient has failed one salvage (re-induction) (Failure or relapse after CR2)
•4. Eastern Cooperative Group (ECOG) performance status = 2
•5. Laboratory values as follows:
•Electrolyte panel WNL for the institution (potassium and magnesium values < lower
•limit of normal must be corrected to WNL prior to dosing)
•Total calcium (corrected for albumin) or ionized calcium WNL for the institution
•AST/SGOT and ALT/SGPT = 2.5 x ULN (NCI CTCAE Gr 1)
•Serum creatinine = 1.5 x ULN (NCI CTCAE Gr 1)
•Serum bilirubin = 1.5 x ULN unless attributed to underlying disease (NCI CTCAE Gr 1)
•INR = 1.5 and PTT WNL. Patients receiving anticoagulation therapy (e.g. coumadin,
•heparin) are eligible provided anticoagulation therapy can be discontinued or changed
•to parenteral medications while the platelet count is less than 50,000/mm3
•Negative serum pregnancy test (within 7 days of first dose)
•Negative urine pregnancy test immediately prior to first dose
•Clinically euthyroid (hypothyroidism corrected with supplementation is permitted)
•6. Patient has received a minimum of one and a maximum of three administrations of conventional remission induction therapy (this may include consolidation and/or HSCT) for newly diagnosed AML
•7. Previous therapy for AML has stopped at least 2 weeks or at least five half lives,
•whichever is longer, before the first dose of study drug
•8. Patient has recovered from toxicity of previous AML treatment, including Grade =1 1 non-hematologic toxicity prior to the first dose of study drug
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•5.1.4 Stratum A or B General Exclusion Criteria
•1. Patients with initial diagnosis of AML secondary to ionizing radiation/cytotoxic therapy (e.g. alkylating agents) for previous malignancy
•2. Patients requiring valproic acid for any medical condition during the study or within 5 days prior to the first dose of study drug
•3. Clinical symptoms suggesting CNS leukemia (patients with neurologic symptoms must undergo lumbar puncture and a CT scan or MRI of the brain to exclude CNS involvement)
•4. Patients receiving supportive therapy related to complications of allogeneic transplantation, including infections or GVH directed therapy
•5. Patients who have received either hydroxyurea or glucocorticosteroids for prevention of leukostasis less than 24 hours before the first dose of study drug
•6. Patients with another malignancy (with the exception of prior MDS in patients with initial diagnosis of AML secondary to MDS/AHD) unless disease-free for at least 3 years following the completion of curative intent therapy. Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasm regardless of the disease-free duration, are eligible if definitive treatment for the condition has been completed.
•7. Patients with impaired cardiac function including any of the following:
•Complete left bundle branch block or use of a permanent cardiac pacemaker, congenital long QT syndrome, history or presence of ventricular tachyarrhythmias,
•clinically significant resting bradycardia (<50 beats per minute), QTcF = 450 ms on
•screening ECG, or right bundle branch block + left anterior hemiblock (bifascicular
•LVEF< lower limit of institutional normal, as assessed by ECHO or MUGA
•Presence of unstable atrial fibrillation (ventricular response rate >100 bpm). Patients with stable atrial fibrillation are eligible provided they do not meet the other cardiac exclusion criteria
•Angina pectoris or acute MI within 6 months
•Other clinically significant heart disease (e.g. uncontrolled hypertension or history of poor compliance with an antihypertensive regimen)
•8. Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled
•diabetes mellitus, chronic obstructive or chronic restrictive pulmonary disease including dyspnea at rest from any cause) or history of serious organ dysfunction or disease involving the heart, kidney or liver and/or known seropositive HIV (HIV screening testing is not required)
•9. Patient has an impairment of gastrointestinal (GI) function or GI disease that may
•significantly alter the absorption of oral panobinostat (e.g., ulcerative disease,
•uncontrolled vomiting, grade > 1 diarrhea, malabsorption syndrome, obstruction, or
•stomach and/or small bowel resection)
•10. Psychiatric disorder that interferes with ability to understand the study and give informed consent, and/or would impact study participation or follow-up
•11. Concurrent use of medications that have a relative risk of prolonging the QT interval or of inducing Torsade de Pointes, if such treatment cannot be discontinued or switched to a different medication prior to the first dose of study drug
•12. Female patients who are pregnant or breast-feeding or patients of childbearing potential (WOCBP) not willing to use a double barrier method of contraception during the study and for 3 months following the last dose of study drug. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or surgical steriliz

研究者

发起方

ovartis Pharma Services AG

相似试验

进行中（未招募）

不适用

A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML) - N/APatients with refractory de novo or secondary acute myelogenous leukemia (AML)MedDRA version: 9.1Level: LLTClassification code 10000886Term: Acute myeloid leukemia

EUCTR2008-002983-32-FRovartis Pharma Services AG164

已完成

不适用

A Phase II Study of Oral Single Agent Panobinostat in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)-C92 Myeloid leukaemiaMyeloid leukaemiaC92

PER-137-09OVARTIS BIOSCIENSES PERU S.A.,1

进行中（未招募）

不适用

A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML) - N/APatients with refractory de novo or secondary acute myelogenous leukemia (AML)MedDRA version: 14.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2008-002983-32-DEovartis Pharma Services AG164

进行中（未招募）

不适用

EUCTR2008-002983-32-GRovartis Pharma Services AG164

进行中（未招募）

1 期

EUCTR2008-002983-32-BEovartis Pharma Services AG164